🇺🇸 FDA
Patent

US 8367734

Stable epinephrine suspension formulation with high inhalation delivery efficiency

granted A61KA61K31/137A61K9/008

Quick answer

US patent 8367734 (Stable epinephrine suspension formulation with high inhalation delivery efficiency) held by Amphastar Pharmaceuticals, Inc. expires Mon Jan 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Amphastar Pharmaceuticals, Inc.
Grant date
Tue Feb 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/137, A61K9/008